Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline.
Since publication of the 2011 American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy (HCM), more recent studies offer greater insights about this condition. With increased recognition of the role of sarcomere protein mutations and myocardial structural abnormalities in the pathophysiology of this disease, new evidence offers potential improvements for the management of patients with HCM. In this review of studies published since 2011, we highlight several studies that may impact diagnostic considerations, risk stratification, and treatment of symptoms in HCM.
Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA.
Ariane
A
Fraiche
Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA. a.wang@duke.edu.
Andrew
A
Wang
D000572:American Heart Association; D001281:Atrial Fibrillation / Q000453:epidemiology*; D002309:Cardiology; D002312:Cardiomyopathy, Hypertrophic / Q000150:complications* / Q000000981:diagnostic imaging* / Q000628:therapy*; D016757:Death, Sudden, Cardiac / Q000453:epidemiology*; D006801:Humans; D008279:Magnetic Resonance Imaging; D009206:Myocardium / Q000473:pathology; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D014481:United States
Cardiac magnetic resonance imaging; Hypertrophic cardiomyopathy; Risk stratification; Sudden cardiac death; Treatment